Nicolas Culpeper was recommending it for jaundice in the 1600s. It's still the most extensively studied hepatoprotective herb that exists — and the reason it works isn't folklore, it's Nrf2.
Milk thistle has one of the longer paper trails of any herbal remedy still in common clinical use — European field use for liver and spleen complaints stretches back centuries, and the seventeenth-century herbalist Nicolas Culpeper recommended it explicitly for jaundice. That's not, on its own, evidence. What makes it interesting now is that the mechanism has been worked out in enough molecular detail that the old use case and the modern biochemistry actually line up.
Silybum marianum, the milk thistle plant, contains a complex of flavonolignans collectively called silymarin — the three main constituents are silybin, silydianin and silychristin. When people talk about "silymarin" and "milk thistle extract" more or less interchangeably, this is what they mean. Quality matters enormously here: extracts should be standardised to 70–80% silymarin content, and unstandardised milk thistle products vary wildly in actual active content.
Silymarin doesn't work as a single simple antioxidant mopping up free radicals. It activates Nrf2, the master regulator that switches on the liver's own antioxidant and detoxification gene programme — upregulating glutathione-related enzymes, phase II detox enzymes (NQO1, HO-1), and glutathione S-transferase activity in the process. Separately, it stabilises hepatocyte cell membranes directly, which is part of why it's used clinically in cases of acute mushroom poisoning (an IV silibinin protocol exists specifically for this). And it inhibits the TGF-β/Smad signalling pathway that drives hepatic stellate cell activation — the process that produces fibrotic scarring in chronically stressed livers.
Put simply: it doesn't just defend the liver passively, it tells the liver's own defence systems to switch on, while directly slowing the scarring process that turns liver stress into liver damage.
The strongest and most recent evidence sits in non-alcoholic fatty liver disease: randomised trials and 2024 meta-analyses of NAFLD/NASH patients show silymarin at 140–420mg daily over 8–24 weeks measurably reduces ALT and AST beyond placebo. Evidence in viral hepatitis and alcohol-related liver disease is real but more mixed — a Cochrane review of 13 trials in over 900 patients found benefit in some outcomes but not a consistent, unambiguous signal across all of them. This is a herb where the honest answer is "genuinely useful, especially for metabolic liver stress, not a cure for established liver disease."
Standard hepatoprotective dose: 420mg/day of extract standardised to 70–80% silymarin, in divided doses, for 6–8 weeks, with a maintenance dose of 280mg/day thereafter for ongoing support.
NAFLD-specific trials: as low as 140mg/day still showed benefit over 8–12 weeks, though higher end of the 140–420mg range is more consistent with meaningful ALT/AST reduction.
The bioavailability problem: plain silibinin has notably poor oral bioavailability — well under 1% in some pharmacokinetic work. This is where form genuinely changes outcomes: a silybin-phosphatidylcholine complex (marketed under names like Siliphos) improves absorption several-fold over standard milk thistle capsules. A cheap, unstandardised milk thistle product is one of the clearer cases in supplement evaluation where you are very likely paying for very little active ingredient reaching the liver.
Elevated ALT/AST or GGT on blood chemistry, a history of alcohol use, medication load that includes hepatically-metabolised drugs, or a GI-MAP picture suggesting a sluggish phase II detoxification pathway are all reasonable indications to consider milk thistle as part of a liver-support protocol — alongside addressing the actual driver, not instead of it.
One clinically important interaction worth flagging directly: cholestyramine and other bile-acid sequestrants bind fat-soluble compounds in the gut, and there's a genuine theoretical concern about timing silymarin (a fat-soluble flavonolignan complex) away from a cholestyramine dose, the same way fat-soluble vitamins need to be separated. If a client is on a bile-binding medication, timing separation isn't optional — it's the difference between the milk thistle actually being absorbed and it being bound and excreted unused.
The honest version of this herb's story isn't "ancient remedy vindicated by modern science" as a simple headline. It's closer to: a genuinely active compound complex, real mechanism, real evidence in specific conditions — and a bioavailability problem that most cheap products on the shelf never solve.
Milk thistle is not FDA or MHRA approved for any specific condition, and it should never replace guideline-directed treatment for viral hepatitis or advanced liver disease. It also mildly inhibits CYP2C9 and CYP3A4, so it's worth checking against a client's full medication list, particularly diabetes medications, blood thinners, and immunosuppressants, even though clinically significant interactions at standard doses are uncommon.
Ask AIdan whether your bloods or medication list make milk thistle relevant — or how to time it around other medications correctly.
Ask AIdan → See the TDG Programme